TapewireFind a company

person · Reporting owner

Hanrahan Jessie

Disclosed activity across 1 company

Tapewire entity
51787
SEC CIK
0001954826

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Solid Biosciences Inc.SLDB · Entity 4915Chief Regulatory OfficerJanuary 29, 2026April 21, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Solid Biosciences Inc.

Report date January 29, 2026 · Filed April 21, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible securityDirect54,925 Reported balance After 2026-01-29 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-01-29 · Grant · Acquired 54,925 · Balance 54,925

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
February 18, 2026 Filed Feb 19, 2026 02:34 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 4,134 $5.82 $24,073.52
Disclosure

SEC source: 0001193125-26-057872 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,318

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Read SEC document
February 13, 2026 Filed Feb 19, 2026 02:34 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 8,125 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-057872 · ownership.xml · derivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,250

Underlying: Common Stock · 8,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F4 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F4 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
February 13, 2026 Filed Feb 19, 2026 02:34 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 8,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-057872 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,452

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
February 04, 2026 Filed Feb 6, 2026 22:57 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 12,348 $6.44 $79,544.58
Disclosure

SEC source: 0001193125-26-041507 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,327

F1 · shares: This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Read SEC document
February 02, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 26,535 $6.44 $170,803.14
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · nonDerivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,675

F3 · shares: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 27,625 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · derivative · entry 7

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 82,875

Underlying: Common Stock · 27,625 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

F8 · derivative.exercise_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 110,500 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

F8 · derivative.expiration_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 110,500 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.

Read SEC document
January 31, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 27,625 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,210

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 95,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · derivative · entry 6

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 95,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.

F7 · derivative.exercise_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

F7 · derivative.expiration_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantEmployee Stock Option (Right to Buy) · Derivative 190,000 $0.00 Strike: $6.60 $0.00
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · derivative · entry 5

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2036-01-29

F6 · derivative.exercise_date: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionPerformance Stock Units · Derivative 54,925 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · derivative · entry 4

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 54,925 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

F5 · derivative.exercise_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

F5 · derivative.expiration_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.

Read SEC document
January 29, 2026 Filed Feb 3, 2026 01:15 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 54,925 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-034085 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,585

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis.

Read SEC document
January 29, 2026 Filed Apr 21, 2026 20:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 54,925 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-166731 · ownership.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,925

Underlying: Common Stock · 54,925 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

F2 · derivative.expiration_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.

Read SEC document
December 03, 2025 Filed Dec 4, 2025 21:19 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 4,483 $5.11 $22,908.13
Disclosure

SEC source: 0001193125-25-308108 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,660

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

Read SEC document
December 02, 2025 Filed Dec 4, 2025 21:19 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 11,862 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-308108 · ownership.xml · derivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,863

Underlying: Common Stock · 11,862 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2025 Filed Dec 4, 2025 21:19 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 11,862 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-25-308108 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 31,143

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:14 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 71,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-109728 · ownership.xml · derivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,250

Underlying: Common Stock · 71,250 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

F1 · derivative.expiration_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

Read SEC document
August 14, 2025 Filed Aug 18, 2025 20:14 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantEmployee Stock Option (Right to Buy) · Derivative 142,500 $0.00 Strike: $6.17 $0.00
Disclosure

SEC source: 0000950170-25-109728 · ownership.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,500

Underlying: Common Stock · 142,500 shares

Expires 2035-08-14

F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary.

Read SEC document
February 14, 2025 Filed Feb 18, 2025 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 3,079 $3.96 $12,192.84
Disclosure

SEC source: 0000950170-25-022206 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 19,281

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Dr. Hanrahan on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Hanrahan.

Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 8,125 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-022206 · ownership.xml · derivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,375

Underlying: Common Stock · 8,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
February 13, 2025 Filed Feb 18, 2025 21:05 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 8,125 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-022206 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,360

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
January 31, 2025 Filed Feb 11, 2025 21:43 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 110,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-017979 · ownership.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,500

Underlying: Common Stock · 110,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 03, 2024 Filed Dec 4, 2024 22:34 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 4,610 $5.60 $25,822.45
Disclosure

SEC source: 0000950170-24-133369 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,235

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Dr. Hanrahan.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:34 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 11,862 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-133369 · ownership.xml · derivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,725

Underlying: Common Stock · 11,862 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2024 Filed Dec 4, 2024 22:34 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 11,862 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-133369 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,845

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
February 13, 2024 Filed Feb 16, 2024 17:03 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 32,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-016220 · ownership.xml · derivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
February 13, 2024 Filed Feb 16, 2024 17:03 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantEmployee Stock Option (Right to Buy) · Derivative 65,000 $0.00 Strike: $7.85 $0.00
Disclosure

SEC source: 0000950170-24-016220 · ownership.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2034-02-13

F1 · derivative.exercise_date: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.

Read SEC document
December 04, 2023 Filed Dec 5, 2023 19:30 UTC Solid Biosciences Inc. SLDB · Entity 4915 SaleCommon Stock 4,879 $2.78 $13,561.67
Disclosure

SEC source: 0000950170-23-068064 · ownership.xml · nonDerivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,983

F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1).

Read SEC document
December 02, 2023 Filed Dec 5, 2023 19:30 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionRestricted Stock Units · Derivative 11,862 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-068064 · ownership.xml · derivative · entry 3

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,587

Underlying: Common Stock · 11,862 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2023 Filed Dec 5, 2023 19:30 UTC Solid Biosciences Inc. SLDB · Entity 4915 Exercise / conversionCommon Stock 11,862 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-23-068064 · ownership.xml · nonDerivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,862

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").

Read SEC document
December 02, 2022 Filed Dec 5, 2022 22:47 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantRestricted Stock Units · Derivative 47,449 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-037682 · doc4.xml · derivative · entry 2

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,449

Underlying: Common Stock · 47,449 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs").

F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.

Read SEC document
December 02, 2022 Filed Dec 5, 2022 22:47 UTC Solid Biosciences Inc. SLDB · Entity 4915 GrantStock Option (Right to Buy) · Derivative 94,899 $0.00 Strike: $6.77 $0.00
Disclosure

SEC source: 0000899243-22-037682 · doc4.xml · derivative · entry 1

Hanrahan Jessie · CIK 0001954826 · Chief Regulatory Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,899

Underlying: Common Stock · 94,899 shares

Expires 2032-12-02

F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.